Management of Vasopressors and Inotropes in Neurogenic Shock

First-Line Vasopressor Therapy

Norepinephrine is the first-choice vasopressor for managing neurogenic shock, with an initial target mean arterial pressure (MAP) of 65 mmHg, according to the American College of Cardiology 1
The American Heart Association recommends norepinephrine should be initiated when fluid resuscitation fails to maintain adequate blood pressure in neurogenic shock 1, 2
Early use of vasopressors is recommended as it helps prevent organ failure in shock states, as stated by the American College of Cardiology 1
Administration requires central venous access, and arterial catheter placement is recommended for continuous monitoring, according to the American College of Cardiology 2
The initial target MAP should be 65 mmHg, with individualization based on patient's baseline blood pressure, as recommended by the Society of Critical Care Medicine 3, 1

If target MAP cannot be achieved with norepinephrine alone, consider adding vasopressin to either raise MAP or decrease norepinephrine requirements, as recommended by the Society of Critical Care Medicine 3, 2
Epinephrine can be added to or substituted for norepinephrine as a second-line agent when additional support is needed, according to the Society of Critical Care Medicine 3
Dopamine should only be used as an alternative to norepinephrine in highly selected patients with low risk of tachyarrhythmias or bradycardia, as stated by the Society of Critical Care Medicine 3, 2

Dobutamine is the first-line inotrope when there is evidence of myocardial dysfunction with elevated cardiac filling pressures and low cardiac output, according to the American College of Cardiology 1
Consider adding dobutamine when signs of hypoperfusion persist despite adequate fluid resuscitation and vasopressor therapy, as recommended by the American College of Cardiology 1
The combination of dobutamine and norepinephrine is recommended as first-line treatment in patients with low cardiac output and hypotension, according to the American College of Cardiology 1

Phenylephrine should be reserved for specific circumstances such as when norepinephrine causes serious arrhythmias, when cardiac output is high but blood pressure remains low, or as salvage therapy, as recommended by the Society of Critical Care Medicine 3, 2

All patients requiring vasopressors should have an arterial catheter placed as soon as practical for continuous blood pressure monitoring, according to the American College of Cardiology 1, 2
Titrate inotrope therapy based on improvements in mixed venous oxygen saturation, myocardial function indices, and reduction in lactate levels, as recommended by the American College of Cardiology 1

Vasopressors should not be used as a substitute for adequate fluid resuscitation in hypovolemic states, according to the American College of Cardiology 1
Targeting supranormal cardiac index levels is not recommended and may be harmful, as stated by the American College of Cardiology 1

The American College of Critical Care Medicine recommends that phenylephrine is not used as a first-line vasopressor for neurogenic shock and should only be used in specific salvage situations when norepinephrine has failed or caused serious arrhythmias 4

Phenylephrine impairs microcirculatory perfusion in shock patients, which can worsen tissue hypoxia 5, 6
Phenylephrine decreases stroke volume due to its pure alpha-adrenergic effects, potentially reducing cardiac output 4

Phenylephrine should be reserved for situations where norepinephrine causes serious arrhythmias that are life-threatening 4
Phenylephrine can be used as salvage therapy when all other vasopressor agents have failed to achieve target MAP 4

The typical dosing range for phenylephrine is 0.5-2.0 mcg/kg/min (35-140 mcg/min in a 70-kg adult) 7